|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0029925,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0037747,
umls-concept:C0205179,
umls-concept:C0282460,
umls-concept:C0443220,
umls-concept:C1514162,
umls-concept:C1521808,
umls-concept:C1948023
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-8-28
|
|
pubmed:abstractText |
The purpose of this study was to analyze whether the addition of granulocyte-colony stimulating factor (G-CSF) to platinum-based combination chemotherapy could increase platinum dose intensity and response rates and decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
719-25
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9708936-Adult,
pubmed-meshheading:9708936-Aged,
pubmed-meshheading:9708936-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9708936-Carboplatin,
pubmed-meshheading:9708936-Cisplatin,
pubmed-meshheading:9708936-Combined Modality Therapy,
pubmed-meshheading:9708936-Cyclophosphamide,
pubmed-meshheading:9708936-Dose-Response Relationship, Drug,
pubmed-meshheading:9708936-Drug Administration Schedule,
pubmed-meshheading:9708936-Female,
pubmed-meshheading:9708936-Follow-Up Studies,
pubmed-meshheading:9708936-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9708936-Humans,
pubmed-meshheading:9708936-Middle Aged,
pubmed-meshheading:9708936-Ovarian Neoplasms
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
|
|
pubmed:affiliation |
Division of Medical Oncology, University Hospital 12 Octubre, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
